Your browser is no longer supported. Please, upgrade your browser.
Settings
ONTX Onconova Therapeutics, Inc. daily Stock Chart
ONTX [NASD]
Onconova Therapeutics, Inc.
Index- P/E- EPS (ttm)-16.25 Insider Own4.95% Shs Outstand5.68M Perf Week-16.59%
Market Cap20.56M Forward P/E- EPS next Y-3.02 Insider Trans-26.26% Shs Float5.39M Perf Month-37.59%
Income-21.20M PEG- EPS next Q-0.87 Inst Own54.10% Short Float8.88% Perf Quarter-45.15%
Sales1.30M P/S15.82 EPS this Y39.50% Inst Trans3.02% Short Ratio3.05 Perf Half Y-56.30%
Book/sh1.91 P/B1.90 EPS next Y39.40% ROA-126.30% Target Price15.78 Perf Year-83.33%
Cash/sh3.94 P/C0.92 EPS next 5Y- ROE- 52W Range3.27 - 39.97 Perf YTD-83.91%
Dividend- P/FCF- EPS past 5Y- ROI221.10% 52W High-91.07% Beta1.22
Dividend %- Quick Ratio2.80 Sales past 5Y-55.70% Gross Margin- 52W Low9.17% ATR0.50
Employees25 Current Ratio2.80 Sales Q/Q0.00% Oper. Margin- RSI (14)35.94 Volatility14.45% 13.63%
OptionableNo Debt/Eq0.00 EPS Q/Q91.10% Profit Margin- Rel Volume0.20 Prev Close3.62
ShortableYes LT Debt/Eq0.00 EarningsNov 13 BMO Payout- Avg Volume156.96K Price3.57
Recom2.00 SMA20-13.10% SMA50-30.96% SMA200-53.88% Volume6,205 Change-1.38%
Mar-01-18Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18Downgrade Maxim Group Buy → Hold
Oct-09-17Initiated H.C. Wainwright Buy $6
Apr-27-17Initiated Laidlaw Buy $10
Jul-01-15Upgrade Piper Jaffray Neutral → Overweight
May-05-15Initiated H.C. Wainwright Buy $6
Dec-10-18 07:30AM  Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel GlobeNewswire
Dec-03-18 07:30AM  Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting GlobeNewswire
Nov-16-18 01:47PM  Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
Nov-13-18 07:00AM  Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018 GlobeNewswire -18.20%
Nov-07-18 08:30AM  Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO) GlobeNewswire
Nov-06-18 10:30AM  Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Nov-05-18 08:30AM  Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition GlobeNewswire
Nov-01-18 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results GlobeNewswire +8.56%
Oct-29-18 08:30AM  Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark GlobeNewswire
Oct-17-18 08:30AM  Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib GlobeNewswire
Oct-10-18 08:30AM  Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco GlobeNewswire
Sep-27-18 08:00AM  Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences ACCESSWIRE -11.77%
Sep-26-18 12:12PM  Bucks County biopharm firm implements reverse stock split American City Business Journals
Sep-25-18 09:16AM  Onconova Therapeutics Announces Reverse Stock Split GlobeNewswire
Aug-21-18 09:46AM  Edited Transcript of ONTX earnings conference call or presentation 14-Aug-18 1:00pm GMT Thomson Reuters StreetEvents +6.10%
08:30AM  Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma GlobeNewswire
Aug-14-18 08:00AM  Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018 GlobeNewswire -9.73%
07:00AM  Onconova Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 08:00AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results GlobeNewswire
Jul-17-18 07:25AM  Free Technical Research on OPKO Health and Three More Biotech Equities ACCESSWIRE
Jun-21-18 08:00AM  Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D. GlobeNewswire
Jun-07-18 08:30AM  Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association GlobeNewswire +41.48%
May-29-18 08:00AM  Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational ACCESSWIRE +10.40%
May-25-18 07:21PM  Who Are The Top Investors In Onconova Therapeutics Inc (NASDAQ:ONTX)? Simply Wall St.
May-22-18 07:00AM  Free Technical Insights on OPKO Health and Three Other Biotech Stocks ACCESSWIRE
May-16-18 08:20PM  Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT Thomson Reuters StreetEvents
May-15-18 08:30AM  Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018 GlobeNewswire -6.64%
07:31AM  Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX) Simply Wall St.
May-09-18 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results GlobeNewswire
May-03-18 08:00AM  Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018 GlobeNewswire
May-01-18 08:10PM  Onconova Therapeutics Inc (NASDAQ:ONTX): Does The Earnings Decline Make It An Underperformer? Simply Wall St.
06:33PM  Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering GlobeNewswire
Apr-27-18 06:00AM  Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering GlobeNewswire -7.24%
Apr-19-18 08:30AM  Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting GlobeNewswire
Mar-26-18 08:30AM  Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium GlobeNewswire
Mar-15-18 08:00AM  Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018 GlobeNewswire
Mar-09-18 12:13PM  Edited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMT Thomson Reuters StreetEvents
Mar-08-18 08:00AM  Onconova Therapeutics Inc. to Host Earnings Call ACCESSWIRE -10.92%
Mar-06-18 08:30AM  Onconova Therapeutics to Present at the 30th Annual Roth Conference in March GlobeNewswire
Mar-05-18 08:00AM  Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America GlobeNewswire
Mar-04-18 10:00AM  Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Research (AACR) Epigenetics Conference GlobeNewswire
Mar-01-18 12:00PM  Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2017 Financial Results GlobeNewswire
08:00AM  Onconova to Present Dose Optimization Studies with Rigosertib Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium GlobeNewswire
Feb-20-18 08:30AM  Onconova Announces Two Presentations at 2018 American Chemical Society National Meeting and Expo GlobeNewswire +14.02%
Feb-12-18 03:55PM  Onconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Securities GlobeNewswire
Feb-08-18 06:00AM  Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering GlobeNewswire
Feb-02-18 08:30AM  Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research Conference GlobeNewswire
Jan-17-18 07:30AM  Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis GlobeNewswire
Jan-12-18 03:05PM  Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial GuruFocus.com
Jan-04-18 08:00AM  Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute GlobeNewswire
Dec-28-17 08:30AM  Onconova Therapeutics to Present at Biotech Showcase in January GlobeNewswire
Dec-21-17 07:40AM  Wired News Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300 ACCESSWIRE
Dec-19-17 07:30AM  Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5 GlobeNewswire
Dec-12-17 08:30AM  Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting GlobeNewswire
Dec-08-17 05:53PM  Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Nov-30-17 12:25PM  Does Onconova Therapeutics Incs (ONTX) Past Performance Indicate A Weaker Future? Simply Wall St.
Nov-20-17 08:30AM  Onconova Therapeutics to Present at the LD Micro Conference in December GlobeNewswire
Nov-16-17 08:30AM  Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting GlobeNewswire
Nov-15-17 08:30AM  Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia GlobeNewswire +5.70%
Nov-13-17 08:37AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Capital Cube +5.84%
Nov-10-17 01:15PM  Edited Transcript of ONTX earnings conference call or presentation 9-Nov-17 2:00pm GMT Thomson Reuters StreetEvents -17.16%
07:00AM  Onconova Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-09-17 07:40AM  Onconova Therapeutics Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results GlobeNewswire
06:15AM  Onconova Therapeutics Inc (ONTX): How Does It Impact Your Portfolio? Simply Wall St.
Nov-02-17 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 09:41AM  Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting GlobeNewswire -7.00%
Oct-10-17 08:10AM  Today's Research Reports on Stocks to Watch: Onconova Therapeutics and Sorrento Therapeutics ACCESSWIRE
07:30AM  Onconova Therapeutics to Present Updates at Two Investor Conferences in October GlobeNewswire
Oct-04-17 08:30AM  Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City GlobeNewswire +8.64%
Sep-29-17 09:01AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-21-17 08:30AM  Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates GlobeNewswire +7.86%
Sep-05-17 08:30AM  Onconova Therapeutics to Participate in Two Investor Conferences in September GlobeNewswire
Aug-16-17 06:04PM  Edited Transcript of ONTX earnings conference call or presentation 15-Aug-17 1:00pm GMT Thomson Reuters StreetEvents -10.81%
Aug-15-17 07:30AM  Investor Network: Onconova Therapeutics Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results GlobeNewswire
Aug-08-17 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2017 Financial Results GlobeNewswire
Jul-25-17 08:30AM  Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric RASopathies GlobeNewswire
Jun-26-17 08:30AM  Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid GlobeNewswire
Jun-16-17 02:26PM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
Jun-13-17 08:30AM  Onconova Therapeutics to Present at the BIO International Convention GlobeNewswire
Jun-05-17 09:36AM  UPDATE: Onconova Therapeutics stock surges 7% on positive mid-stage clinical trial results MarketWatch
08:30AM  Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-22-17 08:30AM  Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association GlobeNewswire
May-19-17 08:55PM  Edited Transcript of ONTX earnings conference call or presentation 15-May-17 1:00pm GMT Thomson Reuters StreetEvents
May-18-17 08:30AM  Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-15-17 08:30AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results GlobeNewswire
08:00AM  Investor Network: Onconova Therapeutics Inc. to Host Earnings Call Accesswire
May-04-17 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results GlobeNewswire
May-01-17 08:31AM  Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes GlobeNewswire +5.38%
Apr-26-17 05:26PM  Onconova Therapeutics Announces Closing of Public Offering of Common Stock GlobeNewswire
08:30AM  Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC GlobeNewswire
Apr-21-17 09:55AM  Onconova Therapeutics stock drops 12% after pricing stock offering MarketWatch -15.26%
09:41AM  Onconova Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Apr-20-17 07:47PM  Onconova Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-05-17 11:22AM  Company News for April 05, 2017 Zacks
11:22AM  Company News for April 05, 2017
08:30AM  Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval Accesswire
08:30AM  Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval
Apr-04-17 12:25PM  Onconova Reports Positive Data for 2 Cancer Drugs Investopedia +6.98%
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoffman Michael BDirectorAug 29Sale0.4529,99913,5215,731,117Aug 29 05:22 PM
Hoffman Michael BDirectorAug 28Sale0.4550,00022,5975,761,116Aug 29 05:22 PM
Hoffman Michael BDirectorAug 27Sale0.4520,0009,0705,811,116Aug 29 05:22 PM
Bienen Henry SDirectorMay 29Buy0.3810,0003,80022,724May 31 05:27 PM
683 Capital Management, LLC10% OwnerApr 27Buy0.4311,838,2355,031,25014,503,169May 01 05:14 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerApr 27Buy0.4310,147,0584,312,50012,244,080May 01 04:12 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerFeb 08Buy1.011,100,0001,111,0002,097,022Feb 12 07:12 PM
683 Capital Management, LLC10% OwnerFeb 08Buy1.04200,000207,1202,664,934Feb 12 04:37 PM